Contract manufacturer Nypro is bolstering its medical device capabilities, planning to launch another factory in Ireland and employ 200 people in the process.
Patheon's $225 million buyout last year of Mexico's Banner Pharmacaps gave the contract manufacturer a beachhead in the fast-growing Latin market.
It's a done deal. Patheon has concluded its buyout of Banner Pharmacaps, a move that gives it four more manufacturing operations, 1,200 more employees and a foothold in the rapidly growing Latin market.
Onyx, a South Dakota manufacturer of medical devices, will soon be part of Sparton Corporation, as the industrial devicemaker has inked a deal to buy the company for $43.25 million in cash.
Mayne Pharma, an Australia-based drugmaker, has jumped the Pacific to buy Metrics, a privately owned U.S. niche drug developer and contract manufacturer, in a deal that could reach $120 million.
Baxter International ($BAX) aims to beef up capacity for its plasma-derived meds through its new manufacturing services deal with Sanquin Blood Supply Foundation in the Netherlands.
As a Genetic Engineering & Biotechnology News story reveals, they are embracing strategic partnerships and adding capabilities to their arsenal to ensure long-term success.
Nice Insight has released its own study showing what drug developers hope to do with their CRO and CMO partners.
ScinoPharm is investing NT$1.1 billion ($37.6 million) in the construction of a plant in Tainan, Taiwan. The purpose of the plant: to produce injectable cancer drugs, according to the CMO.
Experts cited by Outsourcing-Pharma contribute the shift to a combination of biopharma companies outsourcing more non-core duties and regulatory pressures that lead them to find alternate providers.